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Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be efficacious to prevent pancreatitis
after endoscopic retrograde cholangiopancreatography (ERCP). However, the target patients, the type of NSAID, the route
of administration and the time of drug delivery remain unclear, as well as the potential efficacy in reducing the severity of
pancreatitis, length of hospital stay and mortality. The objective of the study was to evaluate these questions by performing
a systematic review and meta-analysis.
Methods: Multiple searches were performed in the main databases. Randomized controlled trials (RCTs) comparing NSAIDs
vs. placebo in the prevention of post-ERCP pancreatitis were included. Primary endpoint of the study was the efficacy for
pancreatitis prevention. Sub-analyses were performed to determine the risk reduction in high and low risk patients, and to
define optimal time, route of administration, and type of NSAID. Secondary endpoints were safety, moderate to severe
pancreatitis prevention and reduction of hospital stay and mortality.
Results: Nine RCTs enrolling 2133 patients were included. The risk of pancreatitis was lower in the NSAID group than in the
placebo group (RR 0.51; 95%CI 0.39–0.66). The number needed to treat was 14. The risk of moderate to severe pancreatitis
was also lower in the NSAID group. (RR 0.46; 95%CI 0.28–0.76). No adverse events related to NSAID use were reported.
NSAIDs were effective in both high-risk and unselected patients (RR 0.53; 95%CI 0.30–0.93 and RR 0.57; 95%CI 0.37–0.88). In
the subanalyses, only rectal administration of either indomethacin (RR 0.54; 95%CI 0.38–0.75) or diclofenac (RR 0.42; 95%CI
0.21–0.84) was shown to be effective. There were not enough data to perform a meta-analysis in hospital stay reduction. No
deaths occurred.
Conclusion: A single rectal dose of indomethacin or diclofenac before or immediately after ERCP is safe and prevents
procedure-related pancreatitis both in high risk and in unselected patients.
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Introduction
Endoscopic retrograde cholangiopancreatography (ERCP) is a
widely used procedure that combines upper gastrointestinal
endoscopy and radiography to diagnose and treat bile- and
pancreas-related diseases such as choledocholithiasis, benign and
malignant strictures, and so on. It is estimated that 500,000
procedures are performed annually in the United States [1]. The
most common complication of ERCP is pancreatitis, occurring in
2–9% of patients in unselected prospective series [1]. It is
associated with substantial morbidity and long hospitalization,
although mortality is rare [2,3]. Diagnostic criteria for post-ERCP
pancreatitis (PEP) are new onset of pancreatic-type abdominal
pain and amylase or lipase at least three times the normal rate
more than 24 hours after the procedure requiring hospital
admission or a prolongation of planned admission [4].
It is widely accepted that the local and systemic inflammatory
response induced by ERCP is the physiopathological event that
triggers PEP [5–7]. It has been proposed that phospholipase A2
(PLA2) plays an important role in the pathogenesis of this
inflammatory response [5]. In vitro assays show that non-steroidal
anti-inflammatory drugs (NSAIDs) are potent inhibitors of PLA2
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activity in the serum in patients with severe acute pancreatitis and
indomethacin and diclofenac are the most effective PLA2
inhibitors [8].
The fact that the initial triggering event of PEP is well defined
has prompted researchers to seek out measures for its prevention.
Pancreatic stent is not performed by all endoscopists because stent
insertion may be difficult in patients with small or tortuous ducts,
and there is a risk of pancreatic ductal injury [9]. Furthermore, a
follow-up endoscopy is necessary for stent removal. For all these
reasons, this procedure is not widely applied and an effective
protective pharmacological agent would be of great benefit. The
results of RCTs using nitroglycerine, ceftazidime, somatostatin,
octreotide, antiprotease drugs, glucocorticoids, drugs reducing
sphincter of Oddi pressure, antioxidant drugs, heparin, and
Interleukin-10 have been disappointing [4]. Some studies have
shown a benefit with NSAIDs [10–18], but a practice survey study
performed some years ago showed that they were not widely used
[19]. The main reason quoted was insufficient supporting
evidence, but the authors speculate that clinicians’ scepticism
related to the failure of many other large studies with other
pharmacological agents also played an important role.
Previous meta-analyses have suggested that NSAIDs are
effective in preventing post-ERCP pancreatitis [20–22], and the
ESGE guidelines [4], based on four RCTs, recommend routine
rectal administration of 100 mg of diclofenac or indomethacin
immediately before or after ERCP. For this reason, NSAID use is
increasing rapidly. However, after the publication of more recent
studies, certain clinically relevant issues regarding the drug
administration and the target patients remain unresolved. The
rectal route is uncomfortable and drugs’ absorption may be
erratic. For this reason, it may be useful to determine whether the
parenteral route is also effective. In addition, whether NSAIDs
should be given only to selected patients at high risk of developing
PEP, or to all patient who undergo ERCP, is still a matter of
debate. We conducted a systematic review and meta-analysis in
order to determine the effectiveness of non-rectal and rectal
NSAIDs, to establish the optimal moment of drug delivery and the
most appropriate type of NSAID, and to assess their efficacy
according to risk factors for developing pancreatitis. We also
evaluated their safety and the efficacy for reducing pancreatitis
severity, length of hospital stay, and mortality.
Methods
The study was performed in accordance with the PRISMA
recommendations for systematic reviews and meta-analyses [23].
The PRISMA 2009 checklist is shown in Checklist S1 and the
PRISMA 2009 flow diagram in Figure 1. We did not register the
protocol.
Search strategy
Multiple searches were performed in Scopus, Medline, the
Cochrane Library database and the ISI Web of Knowledge from
1980 to November 2013. Details of the search are shown in
Appendix S1. In addition, the references of the selected articles
and those of significant reviews on the topic were also examined
for articles missed in the previous searches.
Inclusion criteria
Published studies were included if: a) they evaluated the efficacy
of NSAIDs for prevention of post-ERCP pancreatitis; b) they were
randomized controlled trials with a placebo arm; 3) they reported
the incidence of post-ERCP pancreatitis in each arm.
Definitions
Post-ERCP pancreatitis (PEP) was defined according to
previous consensus as: ’’clinical pancreatitis with amylase at least
three times the normal rate more than 24 hours after the
procedure, requiring hospital admission or a prolongation of
planned admission’’ [24]. However, subsequent modified defini-
tions that specified the meaning of ‘‘clinical pancreatitis’’ were also
accepted [4]: ‘‘new or worsened abdominal pain’’ [25], ‘‘typical
pain and symptoms’’ [26] or ‘‘abdominal pain and tenderness’’
[27].
Risk factors for developing PEP were extracted from previous
reviews and meta-analyses [4,28]: female sex, young age,
suspected SOH, prior post-ERCP pancreatitis, recurrent pancre-
atitis, pancreatic duct injection, pancreatic sphincterotomy,
balloon dilatation, difficult or failed cannulation, precut sphinc-
terotomy and ampullectomy.
Regarding the inclusion criteria, a study was considered to
involve high-risk patients when all patients included presented at
least one risk factor. On the other hand, a study was considered to
include unselected patients if the presence of risk factors was not a
criterion for inclusion in the study. In this case, studies could
include either all patients who underwent ERCP or patients with
suspected bile obstruction, which is not considered an independent
risk factor for PEP.
Endpoints of the study
The primary endpoint of the study was the efficacy of NSAIDs
for preventing PEP. This was evaluated by comparing the number
of patients presenting PEP in the NSAIDs group vs. the placebo
group.
Sub-analyses of the primary endpoint were planned to compare
the incidence of PEP according to: a) the type of NSAID
(indomethacin or diclofenac); b) route of administration (rectal or
non-rectal); c) time of administration (before or after ERCP); d)
risk of pancreatitis according to inclusion criteria (high risk or
unselected patients); e) presence of each individual risk factor
(female sex, young age, suspected SOH, prior post-ERCP
pancreatitis, recurrent pancreatitis, pancreatic duct injection,
pancreatic sphincterotomy, balloon dilatation, difficult or failed
cannulation, pre-cut sphincterotomy and ampullectomy); f) the
placement of a pancreatic stent.
Most subanalyses were performed separating the studies in the
subgroup in question according to study design, but the two last
subanalyses (each individual risk factor and the placement of a
pancreatic stent) were based on the data extracted from the
stratified results of each study (i.e. the number of PEP in females
receiving NSAIDs vs. the number of PEP in females receiving
placebo). Studies reporting only the baseline characteristics of
patients (not the incidence of PEP in each subgroup) were not
included.
Secondary endpoints were the efficacy of NSAIDs for reducing
the number of moderate and severe pancreatitis, number of
adverse events related to NSAIDs, length of hospital stay, and
mortality. They were summarized through a quantitative meta-
analysis when feasible, or described otherwise.
Data extraction
Data extraction was performed in duplicate by two observers
(MB & AI). Discordances were resolved by consensus with a third
observer (IP). For each study we extracted the following variables:
first author, year of publication, country, inclusion criteria,
exclusion criteria, the definition of pancreatitis, differences in
baseline risk factors between the groups, the use of pancreatic stent
for PEP prophylaxis, the type, schedule and route of administra-
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tion of the NSAID, the incidence of PEP in all groups, the
incidence of PEP in the subgroup of patients with risk factors
(when stratified results were reported), the incidence of moderate
to severe PEP, adverse events related to NSAID administration,
mortality, and length of hospital stay.
Quality assessment of the studies
Two independent reviewers assessed the quality of trials with
the Jadad scale (AI & IP). In the case of one article published in
Hungarian [11], we contacted the authors who helped us to assess
the Jadad scale. Disagreements were discussed by the reviewers
and resolved through consensus. According to this scale, low-
quality studies had a score of #2 and high-quality studies had a
score of $3 [29].
Statistical analysis
Differences observed between the groups were expressed as risk
ratios (RR) with their 95% confidence intervals (CI). In the case of
primary and secondary endpoints, numbers needed to treat (NNT)
were also calculated. Heterogeneity was measured using the I2 test
and was considered significant when the I2 value was above 50%
[30,31]. A fixed-effects model weighted by the Mantel-Haenszel
method was used for pooling the RR’s because of the low
heterogeneity between studies. Funnel plot was used to estimate
the risk of publication bias. All calculations were performed using
the freeware Review Manager 5.1 (Cochrane Foundation,
McMaster University, Ontario, Canada) [32].
Results
Original searches retrieved more than 1000 articles. After
review of the abstracts, 12 studies met the inclusion criteria. After
careful evaluation, nine were included in the systematic review and
the meta-analysis (Figure 1).
Studies excluded
Three studies were finally excluded from the meta-analysis: 1)
Montan˜o Loza et al [33] reported the preliminary results of
another study which was already included; 2) Katsinelos et al [34]
administered somatostatin along with NSAIDs and found a
significantly lower incidence of PEP in this treatment group
(4.7% vs 10.4%, p= 0.015); 3) Bhatia et al [35] did not find
statistically significant differences when comparing valdecoxib iv
vs. placebo (9.9% vs 10.3%, p= 0.99). This study was excluded
because valdecoxib is a selective COX2 inhibitor. The effect of
coxibs in reducing PLA2 activity is unknown, and therefore they
may not be as effective as conventional NSAID for PEP
prevention.
Figure 1. Flow diagram of included and excluded trials.
doi:10.1371/journal.pone.0092922.g001
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Studies included
Nine studies, all published as full text articles, were included
[10–18]. The characteristics and quality of the studies are shown
in table 1. Six studies were scored as high-quality (Jadad score 5)
[10–13,15,18] and three as low-quality (Jadad score 2) [14,16,17].
According to the inclusion criteria (table 1), three studies
included only high risk patients for PEP: Murray et al [15]
included only patients with pancreatography or cholangiography
and manometrically documented SOH; Khoshbaten et al [13]
included patients with pancreatography with or without cholan-
giography; Elmunzer et al [12] included selected high risk patients
having at least one major or two minor criteria which had been
previously defined. The remaining six studies [10,11,14,16–18]
included unselected patients.
Risk factors for PEP were similar for both the treatment and the
placebo arms in all studies. Only one study [16] reported a
statistically significant difference in sex distribution: 31 women
were included in the diclofenac group vs. 20 in the placebo group;
p value was 0.019.
Pancreatic stent for PEP prophylaxis was placed in selected
patients in four studies [10,12,13,15]. The rate of stent placement
was similar in the NSAID and the placebo groups. Five studies
reported that they did not use pancreatic stent for PEP prophylaxis
[11,14,16–18].
Main exclusion criteria were the same for all the studies: NSAID
use immediately before inclusion in the study, the presence of
active pancreatitis before ERCP and the existence of contraindi-
cations for NSAID administration.
Four studies [10,12,16,18] graded the severity of post-ERCP
pancreatitis according to the criteria proposed by Cotton et al.
[24] and accepted in the current guidelines [4]: mild PEP was
defined as the need for hospital admission or prolongation of
planned admission up to three days; moderate PEP is defined by
the need for hospitalization lasting 4 – 10 days, and severe PEP by
hospitalization for more than 10 days, or necrosis or pseudocyst, or
need for percutaneous drainage or surgical intervention. Montan˜o
Loza et al [14] graded the severity of pancreatitis according to
Ranson’s criteria, while Murray et al [15] graded it according to
CT findings.
Length of hospital stay was reported in different ways. Murray
et al [15] and Elmunzer et al [12] reported the median length of
hospital stay only for the patients who developed PEP in each arm.
Table 1. Basic characteristics of included studies in the meta-analysis.
Author, year,
country N Inclusion criteria
Does the study include
patients with a
pancreatic stent for
PEP prophylaxis? Intervention Definition of PEP Jadad score
Murray, 2003,
Scotland [15]
220 High risk patients
(Pancreatography or
cholangiogaphy with SOH)
Yesa, b 100 mg rectal
diclofenac in
recovery area
Amylase .x4 ULN and






442 Unselected patients (ERCP,
all-comers)




Amylase .x3 ULN and





200 High risk patients
(Pancreatography 6
cholangiography)
Yesa, b 100 mg rectal
diclofenac on arrival
in recovery area
Amylase .x4 ULN and













Amylase .x3 ULN + sharp
pain radiating to back






Yesb 50 mg diclofenac
before and after
ERCP by mouth
Amylase .x3 ULN 18h after







No 75 mg diclofenac
im and i.v. isotonic
after ERCP
Amylase .x3 ULN + epigastric







No 50 mg rectal
diclofenac 30 mins
before ERCP
Amylase .x3 ULN +





602 High risk patients
(1 major or 2 minor
previously defined risk
factors)
Yesb 100 mg rectal
indomethacin
after ERCP
Amylase .x3 ULN +upper
abdominal pain 24 h after











Amylase .x3 ULN, abdominal
pancreatic pain within 24h
after ERCP and extension
of hospitalization
5
aA pancreatic stent was placed only in 25 and 5 patients in these studies.
bNot statistically significant differences between placebo and NSAIDs group.
ERCP: endoscopic retrograde cholangiopancreatography; NSAIDs: non-steroidal anti-inflammatory drugs; PEP: post-ERCP pancreatitis; SOH: sphincter of Oddi
hypertension; ULN: upper limit of normal.
doi:10.1371/journal.pone.0092922.t001
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Cheon et al [10] reported the median length of hospital stay for all
the patients included in each arm, not those with pancreatitis.
Finally, in four additional studies [10,12,16,18] the number of
patients with pancreatitis needing hospitalization for more than
three days could be extracted because they reported the number of
moderate and severe pancreatitis, which had previously been
defined according to hospital stay.
Post-ERCP pancreatitis incidence
Nine studies including 2133 patients reported the number of
cases of pancreatitis in the NSAID and the placebo arms.
Heterogeneity between these studies was low (I2 = 22%). PEP
occurred in 80 out of 1077 patients (7.4%) in the NSAID group vs.
154 out of 1056 patients (14.6%) in the placebo group (RR 0.51;
95% CI 0.39–0.66; p, 0.00001) (Figure 2). NNT was 14. The
funnel plot showed a visual trend suggesting that small studies
reported the highest risk reductions, inducing a publication bias
(Figure 3). However, even though the reduction was lower, large
studies also found a significant reduction in the risk of pancreatitis.
Risk of moderate to severe pancreatitis, adverse events
and mortality and length of hospital stay
Six studies [10,12,14–16,18] reported pancreatitis severity.
NSAIDs were effective in reducing the incidence of moderate to
severe pancreatitis compared with placebo (RR 0.46; 95% CI
0.28–0.76, p = 0.003; I2: 0%) (Figure 4). NNT was 33.
Regarding adverse events, Elmunzer et al [12] reported four
cases of gastrointestinal bleeding in the NSAID group compared to
seven in the placebo group. Cheon et al. [10] reported six cases of
post endoscopic sphincterotomy (ES) bleeding during the proce-
dure in the placebo group and eight cases in the diclofenac group
(P=0.921). Two cases (one in each group) required epinephrine
injection. No cases of delayed bleeding were observed. Senol et al
[17] also reported two cases of post ES bleeding in the control
group and one case in the diclofenac group: all of them were self-
limited and stopped during endoscopy, without intervention. The
remaining studies did not report any NSAID-related adverse
event. No deaths occurred in any study.
A reduced median length hospital stay in patients with
pancreatitis was reported by Murray et al [15] (three days in the
seven patients with pancreatitis in the experimental group vs. five
days in the 17 patients with pancreatitis in the control group, P not
reported) and by Elmunzer et al [12] (3.5 days in the 27 patients
with pancreatitis in the indomethacin group vs. four days in the 52
patients with pancreatitis in the control group, P,0.001). Cheon
et al [10] reported a non-significant reduction in the median
length of hospital stay for all patients in the diclofenac arm.
Hospital stay was 0.73 days in the 105 patients in the diclofenac
group vs. 1.3 days in the 102 patients in the placebo group.
Finally, the number of patients with pancreatitis requiring a
hospital stay of more than three days was reported in four studies
[10,12,16,18]. Meta-analyses considering the number of patients
with hospital stay of more than three days also showed a trend
towards a reduced hospital stay in the experimental group, but the
differences were not significant (RR 0.80; 95% CI 0.53–1.21,
p = 0.3; I2: 0%).
Type of NSAIDs, route and time of administration and risk
factors for PEP
The results of the different sub-analyses are summarized in
Figure 5. Both indomethacin and diclofenac induced statistically
significant reductions in the risk of pancreatitis (RR 0.54; 95% CI
0.38–0.75, p = 0.0002; I2: 0% and RR 0.42; 95% CI 0.21–0.84,
p = 0.01; I2: 54%). Rectal administration was the only effective
route (RR 0.45; 95% CI 0.34–0.61, p,0.0001; I2: 0%), while
other routes – oral in one study and intramuscular in another –
showed a non-significant benefit (RR 0.81; 95% CI 0.47–1.41,
p = 0.46; I2: 22%). NSAIDs were effective when administered
either before or after the ERCP (RR 0.46; 95% CI 0.28–0.74,
p = 0.001; I2: 0% and RR 0.45; 95% CI 0.32–0.64, p,0.0001; I2:
0%), and in both high risk patients and non-selected patients (RR
0.53; 95% CI 0.30–0.93, p = 0.03; I2: 58% and RR 0.57; 95% CI
0.37–0.88; I2: 23%, p= 0.01).
Few studies reported the incidence of PEP according to each
risk factor. In order to avoid misleading results, studies that
administered NSAIDs through non-rectal routes (which did not
prove effective) were not considered. Rectal administration of
NSAIDs was effective in young people and females and did not
depend on whether a sphincterotomy or pancreatography was
performed. NSAIDs were also equally effective in patients with and
without suspected or confirmed sphincter of Oddi hypertension
(table 2). NSAIDs showed a benefit regardless of the placement or
non-placement of a prophylactic stent. By contrast, they were not
effective in old patients and in men. The data available for other risk
factors were insufficient to perform a meta-analysis.
Figure 2. Meta-analysis comparing NSAIDs vs. placebo in reducing the number of patients with PEP. CI, confidence interval; M-H,
Mantel-Haenszel; NSAIDs, non-steroidal anti-inflammatory drugs.
doi:10.1371/journal.pone.0092922.g002
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Discussion
The present study showed that rectal administration of
indomethacin or diclofenac, before or after ERCP, is an
efficacious and safe measure for reducing the incidence and the
severity of post-ERCP pancreatitis. According to the current data,
either diclofenac or indomethacin can be used interchangeably. A
single rectal dose administered either before or immediately after
ERCP seems the most suitable schedule. The sub-analysis showed
that rectal NSAIDs were beneficial in both high-risk patients
(including those with sphincterotomy, pancreatography and
suspected or confirmed SOH) and in unselected patients. Finally,
rectal NSAIDs appear to be effective whether or not a
prophylactic pancreatic stent was inserted.
Two previous meta-analyses with few studies conclude that
NSAIDs are effective in preventing PEP [20,21]. The recent meta-
analysis published by Ding et al [22] includes additional studies,
but one was reported only in abstract form and is as yet
unpublished as a full text, and another evaluated the use of
the Cox2 inhibitor valdecoxib. The authors conclude that
NSAIDs reduce the incidence and severity of PEP. However,
our meta-analysis, including an additional randomized controlled
trial [11], determines that the evidence is conclusive only for rectal
NSAIDs. In addition, our study highlights some clinically relevant
issues: rectal NSAIDs may be administered either before or after
ERCP, both indomethacin and diclofenac seem effective, and
NSAIDs are effective in both selected and unselected patients.
These data agree with previous sub-analyses published by Zheng
et al [36]. Although a trend towards reducing length of hospital
stay was observed, few data were reported in the studies and so this
cannot be confirmed.
A first limitation of the meta-analysis is a possible overestima-
tion of the risk reduction because of the high prevalence of PEP in
the control group of the included studies (7–26%). This high
incidence contrasts with the rates reported in previous series that
range from 1% to 10% [25,28,37]. A reasonable explanation for
this high complication rate is that many studies include high-risk
patients. Another possible limitation is that a proportion of the
studies [14,16,17] were rated as low-quality (Jadad= 2) [38].
However, the risk reduction observed when low-quality studies
were excluded was very similar to those of the main analysis (RR
0.55; 95% CI 0.42–0.73, I2: 33%, data not shown). In addition,
Figure 3. Funnel plot of the meta-analysis.
doi:10.1371/journal.pone.0092922.g003
Figure 4. Meta-analysis comparing NSAIDs vs. placebo in reducing the number of moderate to severe pancreatitis. CI, confidence
interval; M-H, Mantel-Haenszel; NSAIDs, non-steroidal anti-inflammatory drugs.
doi:10.1371/journal.pone.0092922.g004
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severity of pancreatitis was assessed by Ranson’s criteria in one
study [14] and by CT findings in another [15], rather than using
the currently accepted consensus definition proposed by Cotton
[4]. However the risk reduction of moderate and severe
pancreatitis when these studies were excluded was also very
similar to the main group analysis (RR 0.47; 95% CI 0.28–0.80,
data not shown). Finally, some of the sub-analyses should be
interpreted with great caution because they include few studies
and a low number of patients. The reduced power of some of the
comparisons may explain the non-significant results in males and
older age.
Our findings suggest that rectal NSAIDs are also effective when a
pancreatic stent is placed. Elmunzer et al. [39] concludes in a post
hoc analysis that rectal indomethacin could replace the placement
of pancreatic stents. However, no RCTs comparing rectal NSAIDs
alone vs. NSAIDs plus pancreatic stent placement have been carried
out to date. Combinations of these agents, which act on different
steps in the pathogenesis of post-ERCP pancreatitis, may reduce
PEP even more in selected high risk patients, but adequately
performed RCTs are needed to confirm this point.
In conclusion, there is evidence supporting the rectal admin-
istration of indomethacin or diclofenac, either before or immedi-
ately after ERCP. There is no evidence to recommend oral or
Figure 5. Summary of subanalyses comparing NSAIDs vs. placebo in reducing the number of patients with PEP according to: type
of NSAID, route and time of administration and patients inclusion criteria.
doi:10.1371/journal.pone.0092922.g005
Table 2. Subanalysis: rectal NSAIDs vs. placebo in reducing the number of pancreatitis in subgroup of patients with a risk factor.




Young patients 2 [12,18] 527 0.50 (0.30–0.83) 0%
Old patientsa 2 [12,18] 570 0.57 (0.32, 1.05) 0%
Sex
Females 2 [12,18] 513 0.54 (0.34–0.85) 0%
Males 2 [12,18] 327 0.54 (0.23, 1.24) 8%
Sphincterotomy
Yes 4 [12,15,16,18] 786 0.53 (0.35–0.83) 0%
No 4 [12,15,16,18] 572 0.41 (0.23–0.72) 0%
Suspected or confirmed SOH
Yes 2 [12,15] 662 0.50 (0.31–0.83) 10%
No 2 [12,15] 274 0.36 (0.17–0.77) 0%
Pancreatic duct injection
Yes 3 [13,15,18] 454 0.29 (0.13–0.63) 0%
No 1 [18] 348 0.62 (0.21–1.80) -
Prophylactic pancreatic stentb
Yes 1 [12] 496 0.61 (0.38–0.98) -
No 5 [11,12,16–18] 960 0.45 (0.28–0.70) 0%
SOH: sphincter of Oddi hypertension; ERCP: endoscopic retrograde cholangiopancreatography; NSAIDs: non-steroidal anti-inflammatory drugs.
aThe two different studies used different cut-off values to separate young and old patients, one using 45 years and the other 60 years.
bProphylactic measure, not risk factor.
doi:10.1371/journal.pone.0092922.t002
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parenteral administration. Rectal NSAID seem to be safe and
effective in reducing the incidence and the severity of post-ERCP
pancreatitis, both in high risk patients and unselected patients.
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